Publications


Sponsored
  • Value creation in the MedTech industry has recently slowed
  • Companies face disruptions from a volatile macroeconomic environment, unpredictable supply chains, and rising geopolitical tensions
  • Traditional firms face challenges with mature products in slow-growing markets, compounded by predominantly older, mostly male, senior managers
  • Leaders must revamp their people strategies to support growth, enhance value, and boost competitiveness
  • Attracting, developing, and retaining Generation Z talent helps maintain a strong leadership pipeline and long-term agility

Is MedTech ready for Gen Z?

In the dynamic landscape of MedTech, innovation, digital expertise, adaptability, and a deep understanding of market trends are essential for success. The industry stands as a testament to US manufacturing prowess, characterised by rapid innovation and exacting development processes. However, traditional enterprises with established product portfolios in slow-growing markets, led predominantly by older managers, may be challenged to maintain and enhance their success in the coming decade. Integrating Generation Z (Gen Z) into the workforce presents a potential solution. As digital natives, Gen Z is adept at leveraging new technologies, values access to information, and prioritises sustainability, diversity, and inclusivity - traits they expect corporations to embody. Yet, attracting and retaining their talent requires traditional corporations to undergo cultural adaptations.

The current leadership demographic within large MedTechs is predominantly older males, with the average age of C-suite executives ~56 and a substantial proportion of managers >50. Despite women constituting ~50% of the workforce and making most household healthcare decisions, they occupy only ~23% of executive leadership roles in the largest medical device companies. This senior management composition underscores the experience and industry-specific knowledge deemed necessary for these positions, with many executives having >25 years in the field. However, the traditional approaches and possible resistance to change within this group can conflict with the aspirations of Gen Z employees, creating barriers to an inclusive and innovative work environment.

As the MedTech industry anticipates changes in the next five to ten years, integrating the younger generation into the workforce is essential for ensuring sustained growth, and enhanced value. Their adeptness with digital technology, novel viewpoints, and alignment with contemporary values are indispensable for fostering innovation and securing a leading position in the market. Effectively harmonising the seasoned expertise and stability of senior managers with the dynamism and digital fluency of Gen Z employees is critical for the future success of MedTech companies, despite the challenges it entails.

A March 2024 report from Newsweek revealed that ~40% of hiring managers exhibit an age bias against younger candidates. If such bias exists in the MedTech industry, it poses an obstacle to integrate Gen Z capabilities into the workforce. Additionally, seasoned managers may undervalue the skills and potential of younger employees, thereby limiting opportunities for them despite their competencies. Addressing these issues is necessary to create a diverse and inclusive workplace where talent is prioritised over age, ensuring the future success of traditional companies.

 
Technological Adaptability

Integrating Gen Z into MedTechs introduces a familiarity with modern technology. Growing up with the internet, smartphones, and social media has endowed this generation with digital fluency. Their adeptness in navigating and leveraging new social tools is indispensable for companies that depend on technological advancements.
In contrast, older managers, despite their experience, may not possess the same level of comfort and proficiency with emerging technologies. This generational technology gap can lead to slower adoption of innovative solutions and impede the company's progress. Recruiting younger employees helps enterprises adopt the latest technologies and integrate them into their operations.
You might also like:

Reimagining Boards
Innovation is the lifeblood of the MedTech industry. Gen Z, with their perspectives and forward-thinking mindset, can drive the development of new products and services. They are more inclined to think creatively, challenge established norms, foster cross-functional collaboration, and propose novel solutions to existing problems. This spirit of innovation can encourage corporations to develop new offerings that meet the evolving needs of healthcare providers and patients.

Understanding Market Trends

As older generations become a significant market segment, they will drive demand for age-related health solutions and services. Recognising their needs, preferences, behaviours, and expectations is essential for effective product development and marketing. This is why integrating Gen Z employees, who possess expertise in modern tools, social media, and innovative trends can help companies effectively connect with both older and younger consumers by offering new insights. Their perspectives complement the experience of seasoned managers, ensuring the company remains attuned to current market dynamics. Additionally, their expertise in digital marketing and understanding of online consumer behaviour can enhance an enterprise's market relevance through targeted campaigns and engaging digital platforms.

You might also like:

The Silent Obstacle to MedTech Growth and Value Creation

Corporate Culture

Corporate culture is pivotal in attracting and retaining talent. Gen Z values inclusive, diverse, and flexible workplaces that support continuous learning, offer growth opportunities, and foster a sense of belonging. In contrast, incumbent managers may not always prioritise these aspects, leading to a culture that fails to resonate with younger employees and complicates recruitment efforts. New team members are likely to drive initiatives that promote diversity and inclusion, advocate for flexible work arrangements, and champion continuous learning and development.
This cultural shift not only attracts talent but also enhances employee satisfaction and retention. A company whose corporate culture values and supports younger employees, offering them career advancement prospects, fosters their sense of loyalty and commitment. When provided with a supportive and engaging work environment, Gen Z is more likely to remain and contribute to the enterprise's long-term success. By investing in their professional development and recognising their contributions, corporations can retain top talent and build a strong workforce for the future.

Leadership Pipelines

Ensuring a robust leadership pipeline is crucial for the sustainability of MedTechs, especially as long-tenured managers retire. Gen Z, with their innovative ideas, are well-positioned to become the future leaders of the industry. Developing this pipeline requires intentional strategies and programmes. Companies must invest in leadership development initiatives that identify and nurture young talent, provide opportunities for career advancement and encourage cross-functional collaboration.

Effective transfer of expertise from older to younger employees is important for maintaining continuity and leveraging the experience of seasoned managers. This preserves valuable insights, helps to bridge the generation gap and fosters a culture of mutual respect and collaboration. It also contributes to a vibrant corporate culture that values diversity, continuous learning, and innovation, ultimately enhancing the company’s market position and long-term success.

 
Agility and Responsiveness

The MedTech industry is marked by rapid shifts and frequent disruptions, necessitating companies to maintain adaptability and quick responsiveness to stay ahead. Established managers often possess crisis management experience, but may exhibit less flexibility and slower response times. In contrast, Gen Z excels in dynamic environments, embraces innovation and drives swift reactions. They introduce urgency and a readiness to experiment with novel approaches, bolstering an enterprise’s capability to quickly adapt to emerging technologies, evolving market conditions, and new regulatory requirements.

This flexibility is crucial for long-term success in the industry. Gen Z’s perspectives can contribute to strategic decisions that drive growth and innovation. They are more likely to challenge traditional business models, explore new markets, and advocate for bold strategies that position the corporation for future success. Incorporating younger talent into decision-making processes can lead to more innovative and forward-thinking approaches. Their insights, together with the experience of seasoned managers, can help enterprises stay ahead of industry trends, capitalise on emerging opportunities, and maintain a leading position.

 
Risks of Not Integrating Younger Talent

An established management team may resist change, leading to a gradual decline in innovation. Such unintentional resistance can stifle the development of new products and technologies, ultimately causing a loss of market share. As market trends and consumer preferences evolve, companies must adapt to stay relevant. A long-standing management team may be challenged to keep pace with these changes, resulting in products and services that fail to resonate with the market, thereby reducing customer loyalty and revenue.

In the MedTech industry, continuous innovation and adaptation are crucial for maintaining a competitive edge. Without the input and influence of Gen Z, corporations risk falling behind more progressive competitors, jeopardising long-term growth and success. Integrating younger talent can help companies remain agile, forward-thinking, and in tune with the latest market demands.

 
Recruitment Challenges and Solutions

To effectively recruit and retain Gen Z, MedTech companies need to adapt their corporate cultures and managerial styles to align with the young workforce's expectations. Shifting from a top-down approach to one that values collaboration and inclusivity is crucial. Prioritising work-life balance is essential, as nearly half of Gen Z values it highly in their employment choices. Addressing mental health proactively and providing resources and support can appeal to and retain young talent.

Offering skill development and clear career progression pathways is vital, as a significant portion of Gen Z is willing to leave jobs that lack these opportunities. Managers should focus on understanding individual strengths and preferences, providing tailored coaching and assignments to enhance job satisfaction and performance. Building genuine connections through empathy and honest communication cultivates a supportive work environment and increases loyalty. Flexible work patterns, such as hybrid working, flexible hours, or compressed work weeks, accommodate diverse lifestyles, boosting satisfaction and productivity. 

To address generational divides, companies should implement coaching initiatives and encourage collaborative innovation. Bridging the gap between younger and older employees requires open dialogue, mutual respect, and a willingness to learn from each other's strengths. By developing an inclusive culture that values contributions from all employees, companies can create a cohesive and dynamic workplace, enhancing productivity, and employee satisfaction.

 
Takeaways

The MedTech industry faces a critical moment as value creation slows amidst market disruptions and a challenging macroeconomic landscape. Traditional companies, with mature product portfolios and established leadership, often struggle to maintain agility and adaptability. To navigate these challenges and ensure future growth, leaders should prioritise recruiting, developing, and retaining Gen Z employees. This generation brings crucial digital fluency, fresh perspectives, and a commitment to values like sustainability and inclusivity. Their integration into the workforce is critical for driving creativity and maintaining a competitive edge.

Addressing age biases is important to unlock the potential of Gen Z, fostering a dynamic corporate culture that values inclusion and continuous learning. Balancing the experience of seasoned managers with the digital proficiency of younger employees is key to creating a supportive environment that encourages creativity and adaptability. 

Will MedTech companies be ready to embrace Gen Z's capabilities and perspectives to enhance the industry's responsiveness to market trends and consumer needs? 
view in full page
  • FDA scrutiny, financial pressures, and M&A inefficiencies push MedTech leaders to prioritise short-term issues over long-term strategies
  • Balancing short-term compliance with long-term strategic planning is crucial for survival
  • Innovation hubs, agile methodologies, customer engagement, and cross-functional teams are key to future growth and competitive advantage
 
A Playbook for MedTech Success
 
In December 2023, FDA compliance leaders convened at a conference hosted by the US Food and Drug Law Institute (FDLI) in Washington, DC, to discuss the year’s trends and plans for 2024. Keisha Thomas, the FDA’s Associate Director for Compliance and Quality, highlighted key issues from 2023, reporting that 89 inspections had identified violations requiring Corrective and Preventive Actions (CAPAs). Additionally, there were 790 device recalls, and ~70% of 28 device warning letters were associated with the use of unapproved devices. Thomas emphasised that in 2024, the FDA would target companies with a record of repeated infringements, “We’re developing strategies for addressing companies that are in and out of compliance within a short period of time,” she said. By June 5, 2024, the FDA had issued >45 recalls for medical devices.

Regulatory breaches arise from factors such as non-compliance, quality control issues, incomplete documentation, insufficient testing, inadequate risk management, poor communication and training, delayed reporting, lack of post-market surveillance, design failures, supply chain issues, and failure to implement corrective actions. Effective management of these issues requires comprehensive diligence.

However, these process-oriented challenges often do not receive the attention they require for optimal integration following acquisitions. MedTech companies have historically relied on mergers and acquisitions (M&A) as their primary growth strategy. While this approach has typically resulted in financial gains and increased company size, it has not always improved operational efficiency or quality. The financial complexities of M&A transactions often consume company resources, leading to insufficient attention to critical non-financial operational processes, which can increase the risk of non-compliance with FDA regulations.

To tackle these challenges, companies should prioritise digitising their production processes to boost operational efficiency and compliance, ensuring that growth does not compromise quality or safety. Heightened FDA scrutiny can divert resources from integration and process improvements to remediation efforts, which can be detrimental in a rapidly evolving healthcare landscape marked by advancing technologies and increasing investor scepticism.

Over the next decade, traditional companies must undergo transformations to generate new value for patients and shareholders. This requires rebuilding robust supply chains and leveraging the benefits of digitisation and Industry 4.0. Companies should be able to address FDA warning letters, while redesigning manufacturing and distribution networks, improving flexibility, driving innovation, and expanding market access. To support these initiatives, a strategic playbook is essential for driving growth, enhancing value, and boosting competitive advantage. Leaders must balance short-term compliance with forward-looking strategies to ensure long-term success.

 
In this Commentary

This Commentary provides a guide for MedTech leaders navigating the rapidly evolving healthcare ecosystem. It highlights key challenges such as heightened FDA scrutiny, financial pressures, and operational inefficiencies often resulting from sub-optimal M&A integration. The discussion underscores the importance of balancing short-term compliance with long-term strategic planning to sustain growth and maintain competitive advantage. Key strategies include continuous investment in research and development (R&D), integrating digital health solutions, and ensuring regulatory compliance. The Commentary also emphasises the need for enhancing patient-centric solutions, forming strategic partnerships, and maintaining robust talent acquisition and retention practices. Leaders are encouraged to adopt agile methodologies, establish innovation hubs, and leverage cross-functional teams to drive progress and improve market responsiveness. By focusing on these strategic areas, MedTech companies can foster creativity, enhance customer engagement, and ensure sustained growth in the dynamic healthcare landscape.
 
Key Drivers of Growth, Value, and Competitive Advantage
 
Technological Innovation and Integration
Technologically stagnant companies are unstable and prone to failure. Over time, they lose their ability to innovate and address challenges, ultimately leading to their downfall. To stay competitive, MedTech leaders must navigate rapid technological changes, particularly in AI, machine learning (ML), and personalised care. These advancements are transforming diagnostics, treatment, and patient journeys, making continuous innovation essential for increasing growth, enhancing value, and bolstering competitiveness.

Software has become a critical growth driver for companies. This shift requires adopting new approaches to product development and operating models like those of tech companies. Key strategies include: (i) building a resilient solutions stack with engagement, intelligence, and infrastructure layers, (ii) adopting best practices in software development, including reimagining product management, and (iii) strategically sourcing intellectual property (IP) and talent.

Integrating innovative technologies into traditional product lines is essential yet challenging, as it requires new skill sets, robust IT infrastructure, and strategic partnerships with tech firms. This approach can enhance patient engagement, improve outcomes, and streamline healthcare delivery.
Success in technology innovation and integration hinges on merging traditional medical expertise with cutting-edge digital innovations. Healthcare professionals must compliment their medical knowledge with an understanding of technological advancements. Leveraging digital tools like electronic health records, telehealth platforms, and AI enhances patient care. Such integration creates a blend of human expertise and digital innovation, leading to improved patient outcomes, efficient processes, and a more responsive healthcare system.
You might also like:

The Impact of Personalised Healthcare on Traditional MedTechs

Regulatory and Compliance Pressures
Navigating the regulatory landscapes, such as obtaining FDA approval in the US and CE marking in the EU, is both time-consuming and costly. These processes require meticulous documentation, rigorous testing, and continuous compliance, often delaying product launches and increasing expenses. Moreover, ensuring compliance with data privacy laws, such as GDPR in Europe and HIPAA in the US, while leveraging patient data for innovation presents another layer of complexity. Balancing the need for data-driven innovation with stringent privacy and security requirements demands robust data governance frameworks and advanced cybersecurity measures. Enterprises must invest in technologies and practices that protect patient information while still allowing for meaningful data analysis and use. Successfully managing these regulatory and compliance hurdles is critical for maintaining trust, achieving market access, and fostering innovation.
 

Market Dynamics and Competition
Large traditional MedTechs face increasing competition from both peers and start-ups. Every year, start-ups introduce new solutions to the market, often leveraging disruptive technologies and streamlined processes that outpace conventional approaches. To remain competitive, established companies must enhance their agility and speed to market while continuously innovating their product offerings.
 
Expanding into global markets, particularly emerging ones introduces additional obstacles. These markets come with distinct regulatory requirements, unique social and commercial norms, and varied healthcare infrastructures, leading to strategic and operational challenges. Successfully entering and thriving in these regions necessitates an understanding of local regulations, effective partnerships with regional entities, and tailored strategies that address the unique healthcare needs and economic conditions of each market. Navigating these dynamics and competitive pressures, enables MedTechs to unlock new growth opportunities and strengthen their global presence.
 

Cost Management and Efficiency
There are ongoing challenges associated with managing rising expenses. These include expenditures on R&D to stay ahead of technological advancements, costs related to recruiting, developing, and retaining top talent, regulatory compliance to meet stringent global standards, and manufacturing expenses. Balancing these financial demands while maintaining profitability requires strategic planning and resource allocation.
 
Enhancing operational efficiency is important to reduce costs and improve margins without compromising on quality or innovation. This involves streamlining processes, adopting advanced manufacturing techniques, and leveraging automation and digital technologies to optimise production. Additionally, implementing lean management practices can help eliminate waste, reduce lead times, and improve overall productivity. Emphasising cost management and operational efficiency allows companies to maintain their competitive edge, ensuring the efficient and sustainable delivery of high-quality, innovative products to the market.
 

Customer Expectations and Experience
In the evolving healthcare landscape meeting rising customer expectations has become an imperative. This has partly been driven by the shift towards more patient-centric solutions, which necessitates an understanding of patient needs and preferences, enabling companies to deliver personalised solutions and services that enhance outcomes and satisfaction. Embracing this approach requires robust data analytics and feedback mechanisms to ensure that products and services are aligned with customer expectations.
 
Equally important is the strengthening of relationships with providers. Effective collaboration with healthcare professionals is essential for the successful adoption and utilisation of new technologies and products. Companies should focus on creating strong partnerships, offering comprehensive training, support, and integrating their technologies into clinical workflows. Cultivating these relationships ensures that MedTech' innovations are effectively implemented, ultimately improving patient care and operational efficiencies.
 

Talent Acquisition and Retention
MedTechs face obstacles in attracting and retaining a skilled workforce, particularly in specialised areas such as AI, ML, and data analytics. The rapid advancements in these fields necessitate the recruitment of highly qualified professionals who can drive innovation and maintain competitive advantage. A 2023 McKinsey report suggested that demand for individuals with data science and natural-language processing skills is outpacing supply. To stand a chance of recruiting and retaining data scientist successfully, it is crucial for corporations to offer compelling incentives, continuous learning opportunities, and career advancement pathways.
 
Equally important is cultivating a corporate culture that supports innovation, collaboration, and agility. In an industry historically characterised by slow-moving processes, fostering a dynamic and forward-thinking environment is essential. This involves encouraging cross-functional teamwork, embracing new ideas, and being responsive to market changes. Developing a culture that values creativity and flexibility enhances companies'  ability to adapt to emerging trends, attracts top talent, and retains key employees motivated to drive long-term success.
 

Partnerships and Collaborations
Forming strategic partnerships is crucial for driving innovation and accessing new markets. Corporations must collaborate with technology companies, start-ups, and research institutions to leverage cutting-edge advancements and diversify their product offerings. Such partnerships can provide access to disruptive technologies, foster co-development opportunities, and facilitate entry into emerging markets, thereby enhancing the company's growth potential and competitive edge.
 
Additionally, strategically managing M&A is important for integrating new technologies and capabilities. This requires a balance to ensure that the integration of new assets does not disrupt existing operations. Companies must develop robust integration strategies that preserve the value of acquired entities while blending them into the corporate structure. This approach enhances MedTechs' technological capabilities and market reach, ultimately strengthening their industry position and driving sustained innovation and growth.

You might also like:

The Shifting Landscape of ESG Reporting in the MedTech Industry

Sustainability and Social Responsibility
Sustainability and social responsibility are increasingly important challenges for traditional corporations. Adopting sustainable practices in manufacturing and operations is essential to meet both regulatory requirements and stakeholder expectations for environmental responsibility. This involves reducing carbon footprints, minimising waste, and ensuring the responsible use of resources throughout the product lifecycle. Companies that prioritise sustainability can enhance their brand reputation and appeal to a growing segment of environmentally conscious consumers and employees.
Ethical considerations also play a role, particularly in areas such as AI in healthcare, data usage, and informed consent. As AI technologies become integrated into medical devices and healthcare systems, enterprises must ensure that these tools are developed and deployed ethically. This involves safeguarding patient data, ensuring transparency in AI decision-making processes, and obtaining informed consent from patients. Addressing these challenges proactively can build trust with stakeholders and ensure compliance with evolving legal and regulatory standards, ultimately fostering a more responsible and sustainable industry.
 

Funding and Investment
Securing sufficient funding for R&D can be an issue for traditional MedTechs. However, to stay ahead of the innovation curve, continuous investment in technologies and product development is essential. Established companies often face competition from start-ups that have access to venture capital funding, which enables them to innovate rapidly and take risks that larger, more conventional corporations might avoid due to their scale and existing commitments. To remain competitive, established firms must explore diverse funding sources, including strategic partnerships and government grants, while fostering a culture that encourages calculated risk-taking and agile innovation. This approach can help them maintain a leading position in the ever-evolving MedTech landscape.
 
Conquering Challenges

We suggest four initiatives to help MedTechs navigate these challenges, foster innovation, improve market responsiveness, and deliver value to customers, thereby driving growth, enhancing value, and increasing competitive advantage.

Innovation Hubs
It is recommended to establish innovation hubs or incubators within the company. These dedicated spaces are ideal for cultivating new ideas and technologies. Creating an environment that encourages creativity and experimentation enables enterprises to accelerate the development of novel solutions and services. Such hubs can also facilitate partnerships with start-ups, academic institutions, and technology firms, creating a collaborative ecosystem that drives innovation.
  

Agile methodologies
Implementing adaptive methodologies is crucial for speeding up development cycles and enhancing responsiveness to market changes. These practices emphasise iterative progress, flexibility, and close collaboration among team members. Utilising such frameworks allows MedTechs to reduce time-to-market for new products, quickly adapt to regulatory changes, and respond effectively to customer feedback. This adaptability is essential in an industry where technological advancements and market demands evolve rapidly.
 

Customer Engagement
Enhancing customer engagement through digital platforms, feedback loops, and continuous support is another key strategy. Utilising digital tools enables companies to gather real-time feedback from patients and healthcare providers, ensuring that products and services meet their needs. Creating robust support systems and engaging with customers through various digital channels can foster loyalty and trust. Continuous interaction with end-users helps in refining products and delivering superior customer experiences.
 

Cross-Functional Teams
Leveraging cross-functional teams is instrumental in driving integrated solutions that combine hardware, software, and services. These teams, composed of members from diverse departments such as R&D, marketing, sales, and customer service, can collaboratively address complex challenges and create comprehensive solutions. Encouraging interdisciplinary collaboration and eliminating silos enables companies to develop more holistic and innovative products and services that meet the needs of the healthcare industry.
 
Takeaways

The rapid evolution of medical technology markets demands that company leaders balance short- and long-term goals. Increased FDA scrutiny and financial pressures often shift leaders’ focus to immediate concerns, potentially neglecting long-term strategies. Traditional MedTech companies face numerous challenges that require strategic and adaptive approaches to maintain and improve their market position. Cultivating innovation, adaptability, customer engagement, and cross-functional collaboration enables enterprises to thrive in today’s complex healthcare landscape. Prioritising continuous R&D investment, digitisation, and regulatory compliance is essential for staying competitive. Enhancing patient-centric solutions, forming partnerships with start-ups, and attracting top talent are also crucial for driving innovation and market expansion. Embracing innovation hubs, utilising adaptive methodologies, and leveraging cross-functional teams can ensure sustained growth and maintain a competitive edge. Will traditional MedTech companies follow this suggested playbook to create lasting value for patients, shareholders, and the broader healthcare ecosystem or will they stick to their old tricks and hope for the best?
view in full page

What Is an Eye Emergency?
Emergency Eye CareAn eye emergency refers to any sudden or severe eye issue that demands prompt attention from an emergency eye doctor. These emergencies encompass eye injuries, unexpected visual changes, intense eye pain, foreign objects in the eye, chemical exposure, and the sudden appearance of flashing lights or floaters. Conditions such as conjunctivitis, characterized by pain, redness, and discharge, can also lead to an eye emergency.

Upon your visit, the emergency optometrist conducts a thorough examination to assess the type and severity of the issue. This evaluation may involve using specialized equipment, such as a slit lamp, to detect any eye injuries or abnormalities. Treatment options, including medications, eye drops, irrigation, patching, or surgical procedures, depend on the findings.

If you require an emergency eye doctor in Manhattan, consider seeking care from the family eye experts at Eye Physicians in NYC. They offer treatment for both adults and children at their walk-in eye clinic in NYC.

Emergency Eye Care Near Me: Alleviate Your Pain and Preserve Your Vision
When dealing with an injury that affects your eye or causes sudden changes in vision, whether it’s a foreign object, chemical exposure, or other serious conditions, seeking prompt medical attention is essential. Choose an ophthalmologist or optometrist who is available promptly, especially during off-hours or weekends, and has experience in diagnosing and managing eye emergencies like central retinal artery occlusions, chemical injuries, and retinal detachments.

How to Find a Doctor Offering Emergency Eye Care in Your Area
If you’re looking for an emergency eye doctor nearby, here are a few tips:

  • Reach out to friends and family for recommendations.
  • Search online for “emergency eye care near me,” “emergency eye doctor near me,” and “24 hour emergency eye care near me.”
  • Read reviews of local emergency eye doctor online and schedule consultations with them to get to know their practice.

Recognized worldwide as leaders in the field, the ophthalmologists and optometrists at Eye Physicians are more than capable of diagnosing emergency eye problems and offering solutions. We will provide you with the best treatment for your needs to help ensure you have a safe and speedy recovery.

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax: (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

view in full page

Dry eyes can be uncomfortable, as they make reading and other activities tiresome and difficult. Without the appropriate dry eye syndrome treatment, you may develop worse complications that permanently affect your vision. Call the best dry eye syndrome specialists in New York City at Eye Physicians. They know how to provide you with a diagnosis and effectively treat dry eye syndrome, helping you avoid further complications. They work hard to get you in and out of the office in under an hour. So you have no excuses; start treating dry eye syndrome the right way now.

 

What Are the Best Dry Eyes Treatment Options?

The best dry eye treatment for you depends on the severity of the problems and the cause. For an occasional bout of dry eyes that’s not too bothersome, your eye doctor may recommend over-the-counter eye drops.

For more serious dry eye, a dry eye doctor near me in New York City may prescribe dry eye treatments such as:

Prescription eye drops, containing steroids or other medications
Eyelid surgery, in rare instances, a lower eye lid is too loose, and the tears drain too quickly
Punctal plugs, placed in the ducts in the inner corner of your eyes to keep the tears from draining as quickly
The treatments are as individual as you are. If you’re having eye problems in Downtown Manhattan, you need the best dry eye treatments you can find. Contact Eye Physicians for the most accurate diagnoses and effective dry eye treatments in addition to treatment for a wide range of conditions.

 

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax: (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

 

view in full page

Dolce MD in Laguna Beach, CA, brings a personalized touch to healthcare with our concierge doctor services, tailored to the unique needs of Orange County residents. Emphasizing a close patient-physician relationship, we offer comprehensive care that extends beyond the traditional office visit. Our clients enjoy direct access to their family doctor for consultations, ensuring prompt attention and peace of mind. Whether you're seeking IV therapy in Dana Point or general medical advice, our practice is dedicated to maintaining your wellness with a holistic approach. Our concierge medicine service caters to the communities of Laguna Beach, Newport Beach, and Dana Point, providing an elevated healthcare experience that prioritizes your time and well-being.


Address: 310 Glenneyre St, Laguna Beach, CA, 92651
Phone: 949 209-9266

view in full page
  • The rise of false medical information undermines healthcare delivery, fosters mistrust, and exacerbates health crises
  • Social media algorithms, human psychology, and influential personalities can drive the spread of inaccurate information
  • Transparent communication, strategic dissemination of information, and enhanced media literacy are essential for countering false narratives
  • AI can help detect and combat deceptive content, but robust policies and regulations are crucial for its effectiveness
 
Medical Misinformation

On May 20, 2024, the final report of a five-year public inquiry into the UK’s infected blood scandal, chaired by Sir Brian Langstaff, delivered a damning indictment of doctors, successive governments, civil servants and the NHS for misinforming patients about contaminated blood treatments, resulting in >30,000 infections with diseases like HIV and hepatitis C, and causing ~3,000 deaths, with additional fatalities anticipated.

A few hours after Langstaff issued his report, the UK Prime Minister, Rishi Sunak, addressed a packed House of Commons, expressing deep regret  for the failures, stating he was “truly sorry” and the attitude of denial was difficult to comprehend and an “eternal shame”. This scandal underscores a broader and growing concern about medical misinformation, where institutional failures and deliberate obfuscation contribute to public distrust and widespread harm. It highlights the need for transparency and accountability in healthcare systems worldwide.
 
In this Commentary

This Commentary traces the evolution of medical misinformation from myths about Edward Jenner’s late 19th century smallpox vaccine to recent falsehoods, highlighting the roles of digital platforms and socio-political factors. It emphasises the need for healthcare professionals to be vigilant, promote media literacy, advocate public education, and call for strong policies to counteract medical disinformation. Additionally, it examines the dual role of AI in both spreading and combating false health information. By considering an historical context, current challenges, and future strategies, the Commentary aims to enhance understanding and provide solutions to mitigate the impact of medical misinformation on public health.
 
Dead Wrong

Medical misinformation manifests in two primary forms: misrepresenting effective therapies and promoting dangerous treatments. False claims, such as the debunked link between the MMR vaccine and autism, undermine public trust in vaccines, causing decreased vaccination rates and preventable disease outbreaks. Advocacy for harmful treatments, like the opioid epidemic in the US and the tobacco industry's promotion of smoking despite evidence of severe health risks, directly endangers patients and diverts resources from legitimate care. The rise of medical misinformation, fuelled by social media algorithms, human psychology, and influential personalities, exacerbates these threats by fostering harmful behaviours, distrust in medical professionals, and delays in appropriate care. Combating this requires transparent communication, strategic information dissemination, enhanced media literacy, and robust policies and regulations, with AI playing a role in detecting and countering false information to protect public health.
 
In their 2023 publication, "Dead Wrong: Diagnosing and Treating Healthcare’s Misinformation Illness," Geeta Nayyar et al trace the evolution of the phenomenon. One prominent consequence of medical misinformation is vaccine hesitancy, which has persisted from the era of the smallpox vaccine in the late 19th century to the digital age. The book delves into the socio-political dimensions of misinformation, illustrating how political leaders can contribute to vaccine hesitancy and societal divisions. Despite a consensus among researchers, health professionals, and policymakers on the imperative to combat health fabrications, the full scope of this issue remains elusive. Nayyar offers practical strategies for healthcare professionals to confront and reduce the phenomenon.

A 2023 study published in the Journal of Medical Internet Research found that the most prevalent medical falsehoods involve information about smoking, drugs, vaccines, and diseases, with Twitter (now known as ‘X’) identified as a primary platform for their dissemination. Social media amplifies the spread of health misinformation, eroding public trust and impeding medical advancements.
Digital Amplification

Addressing medical falsehoods is important in an era where information spreads rapidly through digital channels. The rise of social media and increased internet accessibility allow misinformation to reach vast audiences within seconds. This challenge is compounded by advancements in AI, which, while contributing to healthcare improvements, also create new avenues for generating and disseminating false information.
You might also like:

Unleashing MedTech's Competitive Edge through Transformational Technologies

 
AI technologies, particularly deep learning and natural language processing, can produce convincing fake content, including medical advice and research findings, exploiting public anxieties and knowledge gaps. To combat this, it is essential to enhance digital literacy, improve the accuracy of AI systems, and foster collaboration among technology companies, healthcare professionals, and policymakers. By understanding and addressing the sources and impacts of medical falsehoods, the protection of public health can be enhanced.
 
Historical Context

Medical misinformation has a long history, dating back to the late 18th century when Edward Jenner, an English physician and scientist known as the father of immunology, pioneered the concept of vaccines and created the world's first smallpox vaccine. Despite its success, Jenner faced significant opposition, fuelled by fear and misunderstanding. Critics spread false claims that vaccination could cause various ailments or even transform individuals into cow-like creatures due to the cowpox origin of the vaccine. This early example highlights the challenges of medical misinformation: fear, misunderstanding, and resistance to new scientific advancements.
 
Throughout the 19th and 20th centuries, the printing press enabled the widespread dissemination of both accurate and inaccurate information. Pamphlets and newspapers often spread falsehoods about anaesthesia and germ theory. The rise of mass media, including radio and television, further amplified inaccurate health information. A notable example is the mid-20th century polio vaccine scare, known as the Cutter Incident, which occurred in April 1955. This involved a batch of polio vaccines produced by Cutter Laboratories that contained live poliovirus, leading to cases of polio among vaccinated children. The Cutter Incident eroded public confidence in the polio vaccine and prompted changes in vaccine production and safety protocols. Additionally, misinformation surrounding the HIV/AIDS epidemic in the late 20th century created fear, stigma, and ignorance as the HIV epidemic raged throughout the world in the 1980s, killing thousands of people.
 
The advent of the internet and social media in the late 20th and early 21st centuries increased the speed and reach of misinformation. Anti-vaccine activism gained traction with the publication of Andrew Wakefield’s now-debunked study in 1998, which falsely linked the MMR (measles, mumps and rubella) vaccine to autism. This led to declines in vaccination rates and subsequent outbreaks of preventable diseases. The COVID-19 pandemic, declared by the World Health Organisation (WHO) in March 2020, further highlighted the impact of medical misinformation, as falsehoods complicated public health efforts and contributed to vaccine hesitancy.
 
Sources and Mechanisms of Medical Misinformation

As we have suggested, medical misinformation spreads through social media platforms, traditional news outlets, and the misinterpretation of scientific studies. Social media platforms like Facebook, X (formerly Twitter), TikTok, and Instagram serve as potent conduits due to their extensive reach and rapid information dissemination capabilities. Often, these platforms lack stringent content inspection mechanisms, enabling unverified information to proliferate through algorithms designed to maximise engagement, which inadvertently prioritises misleading content. Traditional media also contributes to the problem by sensationalising news to attract attention, without adequate fact-checking.
 
Misinformation often goes viral more easily than factual information. A 2018 study in the journal Science found that false information is 70% more likely to be retweeted than the truth. Influencers with large followings further exacerbate the issue by sharing inaccurate information, which quickly gains credibility through their endorsements. Addressing medical misinformation requires a multifaceted approach, including enhanced verification processes, increased public education, and greater accountability for those spreading false information. Additionally, adjusting algorithms, improving media literacy, and promoting credible medical sources are essential steps in combating this pervasive issue.
  
Consequences

Vaccine hesitancy, driven by falsehoods spread online and through social networks, leads people to doubt vaccine safety and efficacy. This hinders vaccination efforts and increases outbreaks of preventable diseases. Inaccurate medical information erodes trust in healthcare professionals and institutions, undermining expert guidance and fuelling public uncertainty and fear. This hampers healthcare delivery and weakens community resilience in crises. Individuals misled by medical falsehoods may make harmful health decisions, such as avoiding recommended treatments or trying dangerous alternative therapies. These effects threaten both personal health and community wellbeing.
 
Case Studies

We have mentioned these examples before, but due to their significance, we are now giving them more prominence.

Smallpox Vaccine Opposition
When Edward Jenner introduced the smallpox vaccine in 1796, scepticism and resistance emerged. Misconceptions about its safety and efficacy, coupled with religious and philosophical beliefs, led some to argue that vaccination interfered with divine will. This resistance delayed smallpox eradication, causing continued outbreaks and fatalities. Persistent public health campaigns and legislative actions eventually overcame this opposition.
 

MMR Vaccine Scandal
In 1998, Andrew Wakefield published a fraudulent research paper falsely linking the MMR vaccine to autism. Despite lacking credible scientific evidence, the publication caused a significant decline in vaccination rates due to media coverage and public fear, leading to outbreaks of measles and other preventable diseases. Subsequent investigations revealed Wakefield's ethical violations and data manipulation, resulting in the retraction of the paper and the revocation of his medical license.

UK Contaminated Blood Scandal
Bleeding disorders are conditions that impair the blood's ability to clot properly. In the UK, ~24,000 people live with such disorders, which are typically inherited, although ~33% of cases result from random gene mutations. The most well-known bleeding disorder is haemophilia A, predominantly affecting males. Those living with the disorders often require transfusions of blood platelets or clotting factors.

Between 1950 and 1970, UK authorities sourced blood donations from prisons. However, the introduction of screening for hepatitis B in the early 1970s revealed a significantly higher incidence of the disorder among inmates. Despite aiming for self-sufficiency in NHS blood stock by July 1977, the UK government failed to achieve this goal and relied on imported blood and blood from prison donors for decades. While countries like Germany and Italy began testing donated blood in the mid-1960s and early 1970s, and the American Red Cross stopped collecting blood from US prisons in 1971 due to high hepatitis rates, the UK continued to import Factor VIII - a blood clotting product - from high-risk US donors, including prison inmates and intravenous drug users, during the 1970s and 1980s. The contaminated blood products led to ~30,000 people in the UK being infected, causing ~3,000 premature deaths. Many survivors contracted HIV and hepatitis C and faced additional challenges such as stigma, job loss, and financial hardship. In 2018, Sir Brian Langstaff was appointed to chair a public inquiry into the UK's contaminated blood scandal. His final report, released on May 20, 2024, highlighted that many infections were preventable and concluded that the tragedy was exacerbated by decades-long cover-ups by doctors, the NHS, governments, and civil servants, driven by "financial and reputational considerations." Langstaff called for immediate compensation, public memorials, and systemic reforms.


The US opioid epidemic
The on-going opioid epidemic in the US further illustrates the impact of medical misinformation. Every day, ~300 Americans die from drug overdoses. According to the Centers for Disease Control and Prevention, there were >100,000 reported overdose deaths in 2021, with opioids involved in ~75% of these cases. Pharmaceutical companies played a significant role in this crisis by misleading healthcare providers and patients, downplaying the addictive risks of opioids, and falsely claiming they were safe for chronic pain management. This misinformation led to widespread over-prescription, resulting in addiction and overdose deaths. Consequently, the opioid epidemic has fuelled a persistent public health crisis that continues to challenge the nation.
 
Combating Medical Misinformation

Effectively combating medical misinformation is challenging, especially when governments and healthcare systems are involved. Addressing this phenomenon requires a multifaceted approach, including proactive public health communication, the involvement of trusted community leaders, and robust social media monitoring. Healthcare professionals and institutions must provide accurate, evidence-based information and act as trusted voices in their communities. Their proactive engagement in patient education and public outreach helps dispel myths and correct falsehoods.
You might also like:

MedTechs Battle with AI for Sustainable Growth and Enhanced Value
Equipping individuals with critical thinking skills to evaluate information sources is essential. Effective strategies to combat misinformation involve utilising a variety of platforms, from traditional media to social networks, ensuring messages reach a broad audience. Clear, consistent, and transparent communication is crucial for building trust and encouraging the public to follow health guidelines.
Policy and regulatory approaches also play an important role. Governments and healthcare organisations must implement regulations to curb the spread of false information, such as holding social media platforms accountable for monitoring and addressing misinformation. Policies should support the training of healthcare professionals in communication skills and media engagement, ensuring they are prepared to counteract misinformation effectively. Integrating these approaches can create a more informed public, enhance trust in healthcare systems, and ultimately improve health outcomes.
 
The Future

The future of medical misinformation will be shaped by emerging trends and technologies, presenting both challenges and opportunities. AI and machine learning (ML) can play roles in detecting and countering falsehoods. Advanced algorithms can analyse vast amounts of data to identify misinformation trends, flagging content that requires further scrutiny. AI-driven chatbots and virtual assistants can provide people with reliable health information, directly counteracting misinformation at its source.
 
Despite these advancements, the use of AI and ML also poses significant risks. These technologies can be exploited to create deepfakes, and if not properly managed, they can inadvertently amplify misinformation, as evidenced by algorithmic biases on social media platforms. To mitigate these risks, ensuring ethical AI deployment and incorporating robust human oversight is crucial. Fostering collaboration between tech companies, healthcare professionals, and policymakers can also establish robust frameworks for managing misinformation. By embracing these technologies while remaining vigilant about their limitations, we can help shape a future where accurate medical information prevails.
 
Takeaways

Geeta Nayyar deserves commendation for her book, which has raised awareness about medical misinformation. Historical and contemporary case studies highlight the evolving threat misinformation poses to public health. Accurate, transparent communication and robust public health strategies are needed. Despite the complexities of combating misinformation, especially when health professionals and governments are involved, healthcare institutions must proactively disseminate reliable information and be accountable for their actions. Media literacy and public education are essential for empowering individuals to navigate the complex information ecosystem. There is a need to leverage advanced technologies, such as AI and ML, which offer promising avenues for detecting and countering misinformation, provided they are implemented with ethical oversight. A multifaceted approach, including policy and regulatory measures, is crucial for safeguarding public health, enhancing trust in healthcare systems, and improving health outcomes.
view in full page

Who Should Consider Cosmetic Dentistry?
Do you cover your mouth when talking to others or feel embarrassed to smile or laugh because your teeth don’t look their best?

Cosmetic dentistry can help, from treating minor imperfections to larger and more complex smile makeovers.

Treatment is worth considering if you have the following problems:

  • Chipped or cracked teeth

From safe, effective teeth whitening to complete smile makeovers, we can help you achieve your dream smile.

  • Gaps between teeth

From safe, effective teeth whitening to complete smile makeovers, we can help you achieve your dream smile.

  • Teeth slightly overlapping

Teeth that are slightly overlapping or not quite perfectly straight From safe, effective teeth whitening to complete smile

  • Teeth ideal shape contour

Teeth that are a less-than-ideal shape, size, or contour From safe, effective teeth whitening to complete smile

  • A gummy smile

Teeth that are slightly overlapping or not quite perfectly straight From safe, effective teeth whitening to complete smile

  • Stained teeth

Teeth that are a less-than-ideal shape, size, or contour From safe, effective teeth whitening to complete smile.

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 

Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657

My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425–9580
Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00 am — 6:00 pm
Saturday: 9:00 am — 3:00 pm
Sunday: by appointment only

Payment: cash, check, credit cards.

view in full page

Why Do You Need a Family Dentist?
Each person has unique oral health care needs that change throughout life. As a family-oriented dental clinic, we can support people of all ages and look after everyone's oral health care needs in one comfortable location.

New Jersey Dentist is a multispecialty dental office offering a wide choice of different dental therapies and treatments.

Everyone visiting our practice receives a custom dental care plan. The plan is based on your dental exam, a review of your medical history and age, and any oral health concerns or desires. Each treatment provided is tailored to accommodate your unique oral health needs.

A family dentist can provide continuity of care so your children grow up trusting dentists and their dental team. A long-term relationship helps our dentist understand your family's oral care needs and provide more personalized care

What Is Family Dentistry?
A family dental office provides a variety of treatments designed to accommodate most oral health care needs. As a multispecialty dental office, we have state-of-the-art equipment and technologies that help us diagnose and treat conditions more efficiently and comfortably.

These technologies include:

  1. Digital x-ray equipment, including panoramic x-rays.
  2. Cone beam CT scan that provides digital 3-D images of teeth and jaws.
  3. 3D scanners for digital dental impressions are more comfortable and accurate than traditional tray impressions
  4. Intraoral cameras to take photos inside your mouth. These images can be magnified and shown on screen, allowing you to see what we see, and so we can explain treatments more easily.

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 

Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657

My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425–9580
Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00 am — 6:00 pm
Saturday: 9:00 am — 3:00 pm
Sunday: by appointment only

Payment: cash, check, credit cards.

view in full page

Dental implants are also called teeth implants and artificially replace missing tooth roots. They consist of metal screws that are inserted permanently into the jawbone during an oral surgery procedure. They can support artificial teeth, including dental crowns, bridges, and implants.

Who Would Need Dental Implants?
If you face losing one or more teeth, you will almost certainly benefit from dental implants. Tooth loss can occur due to the following reasons:

  • Tooth decay
  • Bruxism
  • Gum disease
  • Tooth root fractures
  • Facial trauma
  • Congenitally missing teeth
  • What Are Dental Implants?

A dental implant usually has three components. The first is the threaded screw that is placed into the jawbone. The second is a connector or abutment that is attached to the screw. The third and final component is the implant restoration.

Implant Restorations
When a single implant is placed, this can be an implant crown. Multiple implants can restore teeth using an implant bridge. Implant crowns and bridges are non-removable. They are screwed or cemented onto the abutments

Dental implants can support a removable implant denture. Instead of being screwed or cemented in place, the implant denture clips onto the abutments or a metal bar attached to the abutments.

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 

Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657


My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425-9580

Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00am - 6:00pm
Saturday: 9:00am - 3:00pm
Sunday: by appointment only

Payment: cash, check, credit cards.

view in full page
  • Healthcare is shifting from uniform treatments to personalised care, driven by genetics, lifestyle, and technology
  • Patients benefit from targeted therapies that deliver early disease detection, enhanced therapies and proactive prevention
  • Traditional MedTechs, accustomed to one-size-fits-all devices, face challenges but also can find opportunities from individualised care for growth and innovation
  • To capitalise on these opportunities, conventional corporations must recalibrate their strategies and collaborate with start-ups and healthcare institutions
 
The Impact of Personalised Healthcare on Traditional MedTechs

Personalised medicine, also known as precision medicine, marks a departure from traditional medical practices by acknowledging the interplay of genetics, lifestyle, and environment in shaping an individual's health. Rather than adhering to one-size-fits-all treatments, individualised care prioritises early detection and proactive prevention, tailoring interventions based on each patient's unique genetic makeup. Digitalisation, together with advances in medical technology, enables the combination and analysis of genomic information with other diagnostic data to identify patterns that help to determine an individual’s risk of developing a disease, detect illness earlier, and determine the most effective interventions. For example, in cancer treatment, personalised therapies target specific proteins driving cancer growth, offering more effective alternatives to conventional methods like customary chemotherapy. Findings of a 2012 study published in Trends in Molecular Medicine found that the response rate to a targeted therapy for acute myeloid leukaemia to be at 90% compared with 35% for standard chemotherapy. Another notable development in customised care is the DNA medication pass, which enables clinicians to identify the most suitable drugs for individual patients, reducing adverse reactions and hospital admissions due to drug-related complications. Such personalised approaches empower patients with treatments aligned to their genetic predispositions and foster greater autonomy and engagement in healthcare decisions.

In today's data-driven environment, the emphasis on precision care is growing, and creating a shift in healthcare delivery. A recent research paper published in the Journal of Translational Medicine suggests that personalised medicine will lead to the next generation of healthcare by 2030. While many traditional medical technology companies are content with supplying standardised medical devices to hospitals, an increasing number wish to pivot and capitalise on the rapidly growing targeted healthcare segment. However, they face the challenge of adapting their established frameworks, which are not designed to create bespoke solutions and services. This emphasises the significance of adaptability across diverse healthcare settings. Forward-thinking corporations, however, recognise the need to evolve. By investing in novel R&D initiatives and fostering collaboration throughout the healthcare spectrum, they position themselves favourably. Conversely, companies resistant to change risk stagnation and eventual obsolescence in an era where personalised care is rapidly gaining traction.

 
In this Commentary

This Commentary delves into the impact of personalised healthcare on traditional MedTech companies, highlighting the imperative for alignment with customised care to remain competitive. It explores how targeted medicine, driven by advancements in genetics, digitalisation, and medical technology, is reshaping healthcare delivery by prioritising individualised treatments tailored to patients' unique genetic makeup. The Commentary emphasises the need to adapt conventional strategies amidst industry trends, addressing challenges such as regulatory complexities and technology adoption barriers. Through initiatives like partnerships, novel R&D, diversification, and strategic M&A, traditional MedTechs can position themselves to lead in the era of precision care. The Commentary offers examples of start-ups and established firms addressing this segment, insights into the opportunities and challenges traditional companies face in adapting to the growing emphasis on personalised healthcare, and emphasises the importance of innovation, collaboration, and proactive responses to industry shifts.
 
Brief History

The roots of personalised healthcare can be traced back to ancient civilisations where healers recognised individual differences in response to treatments. However, formalised concepts began to emerge in the late 19th and early 20th centuries with the advent of modern medicine. The discovery of the structure of DNA by James Watson and Francis Crick in 1953 laid the foundation for understanding the role of genetics in health and disease. Advances in DNA sequencing technologies in the late 20th century, particularly the completion of the Human Genome Project in 2003, enabled scientists to decipher the entire human genetic code, ushering in the genomic era.
 
In the late 20th century, researchers began to explore how genetic variations influence an individual's response to drugs. Pharmacogenomics emerged as a field focused on tailoring drug treatments to a person's genetic makeup, aiming to maximise efficacy and minimise adverse effects. Rapid advancements in technology, such as next-generation sequencing and high-throughput screening, have made it more feasible and cost-effective to analyse large amounts of genetic data. This has accelerated research in tailored therapies and expanded their application beyond pharmacogenomics to include risk assessment, disease diagnosis, and treatment selection.
As we suggested, one of the earliest and most successful applications of customised healthcare has been in oncology. Precision oncology uses genomic profiling to identify genetic mutations driving cancer growth and matches patients with targeted therapies designed to address their specific mutations. The success stories in treating certain cancers, such as leukaemia and melanoma have fuelled further interest and investment in personalised approaches.
You might also like:

Healthcare 2040


 
The rise of big data analytics and artificial intelligence (AI) has been instrumental in advancing targeted care. By integrating genetic, clinical, lifestyle, and environmental data, AI algorithms can identify patterns, predict disease risks, and recommend precise interventions targeted to an individual’s unique profile. Governments have recognised the potential of these approaches to improve patient outcomes and reduce healthcare costs. Endeavours such as the Precision Medicine Initiative in the US, the NHS Long Term Plan in the UK, and similar efforts in other countries aim to accelerate the adoption of customised medicine. As technology continues to evolve and our understanding of genetics and biology deepens, personalised healthcare is poised to become increasingly integral to mainstream medical practice, ultimately leading to better health outcomes.
 
Challenges and Barriers to Personalised Care

Customised medicine, while promising, faces challenges. One hurdle lies in the complexity and sheer volume of data required to tailor treatments to individual patients. Integrating diverse datasets from genomics, medical history, lifestyle factors, and environmental influences demands sophisticated analytics and robust privacy safeguards. Additionally, interoperability issues between different healthcare systems impede data exchange and collaboration among healthcare providers. Economic constraints further obstruct widespread adoption, as customised therapies often come with hefty price tags, limiting access for many patients. Regulatory frameworks must also evolve to accommodate the dynamic nature of tailored medicine, ensuring rigorous oversight without stifling innovation. Moreover, educating healthcare professionals and patients about the benefits and limitations of personalised approaches is essential for fostering trust and acceptance. Overcoming these challenges demands interdisciplinary collaboration, technological advancements, and a commitment to equitable access to focussed healthcare.
 
The Changing Landscape of Traditional MedTechs

Despite these challenges, the growing emphasis on personalised care represents a shift in traditional MedTech markets. Although the precise timeline for tailored therapies to substantially influence conventional corporations remains uncertain, the trend signals a clear direction for the industry. The International Consortium for Personalised Medicine (ICPerMed) envisions a healthcare landscape firmly rooted in customised medicine principles by 2030. This vision entails an ecosystem where individual characteristics inform diagnostics, treatments, and preventive measures, resulting in heightened effectiveness and economic value, all while ensuring equitable access for all individuals.
 
Historically, MedTech markets have exhibited a degree of reluctance in adopting new technologies, offering some comfort to conventional leaders in the field. However, the insights provided by the ICPerMed research should serve as a catalyst for traditional enterprises to re-evaluate their strategies and product offerings if they intend to capitalise on the growing trend of customised care. Notably, investments in innovative technologies that facilitate precision diagnostics, targeted therapies, and patient-centric interventions have already proven effective and are on the rise.
You might also like:

Unleashing MedTech's Competitive Edge through Transformational Technologies
Furthermore, the integration of data analytics and remote monitoring capabilities is reshaping the dynamics among medical devices, patients, and healthcare providers. This integration fosters enhanced connectivity and delivers real-time insights, thereby helping to transform the healthcare ecosystem. As tailored care gains momentum, traditional corporations must embrace agility, collaboration, and an understanding of patient preferences to thrive. This necessitates a proactive re-evaluation of their strategies.
Healthcare Firms Leading the Shift Towards Personalised Care

Many early-stage MedTech companies and established healthcare firms are leveraging evolving technologies and data to meet the growing demand for personalised healthcare. Omada Health, for instance, offers a platform combining connected devices and data analytics to help manage chronic conditions through tailored lifestyle interventions. iRhythm Technologies' Zio patch, a wearable cardiac monitor, uses advanced algorithms to detect heart conditions more accurately. Butterfly Network's Butterfly iQ is the first smartphone-connected whole-body ultrasound system, enhancing imaging quality and diagnostic capabilities through AI. Mature enterprises like AliveCor and Fitbit, now part of Google, have also pivoted to tailored healthcare. AliveCor’s  KardiaMobile provides at-home ECGs and shares data for customised treatment plans, while Fitbit offers devices with advanced health monitoring features and personalised wellness programmes. Dexcom's G6 CGM System provides real-time glucose tracking integrated with health data platforms. Roche has shifted towards customised healthcare with digital health solutions like the Roche Diabetes Care platform and the NAVIFY Tumor Board for personalised cancer treatments. 23andMe, initially known for genetic testing, now partners with pharmaceutical companies for drug discovery and develops tailored treatment plans based on genetic data.
 
Transforming MedTech in the Era of Personalised Care

The healthcare industry is undergoing a transformation marked by a shift towards patient-centric care and the adoption of value-based healthcare models. This shift is driving increased collaboration among traditional MedTech firms, healthcare providers, and emerging players, all united in their goal to innovate and tackle the complex challenges facing healthcare today. Regulatory changes and technological advancements also are playing roles in reshaping the competitive landscape, guiding the industry towards more patient-centred, value-driven, and collaborative approaches. In response to these evolving dynamics, MedTech companies are transforming their product development strategies by embracing agile and interdisciplinary approaches. Leveraging digital technologies, they are adapting to changing demands through virtual testing, data-driven design optimisation, and rapid prototyping.
 
The move towards personalised care is not only transforming product development strategies but also reshaping business models within the MedTech industry. There is a growing emphasis on outcome-based pricing and service-oriented solutions, reflecting the industry's focus on delivering measurable results and comprehensive care experiences. Digital health platforms and software-as-a-service (SaaS) offerings are emerging as key drivers of revenue, highlighting the importance of innovation and customer engagement in staying competitive and relevant.
 
Amid these transformations, regulatory and compliance considerations are crucial. Regulatory frameworks are becoming more stringent, emphasising product safety, efficacy, and data privacy. Compliance with varying standards across geographies is essential for market access, requiring companies to navigate these landscapes skilfully to sustain growth. Regulatory bodies are also evolving to tackle emerging challenges like cybersecurity and interoperability, highlighting the need for effective regulatory management in today's MedTech ecosystem. Addressing these challenges demands collaboration among stakeholders to build trust, promote standards, and ease the adoption of innovative technologies. Only through concerted efforts can the industry overcome these obstacles and fully realise the potential of customised care in transforming healthcare delivery.
 
Adaptation Strategies for Traditional MedTech Companies

To strengthen their alignment with personalised healthcare, traditional MedTechs can adopt several strategies. One effective approach, which, in a previous Commentary, we referred to as the Third Way, involves forming partnerships and collaborations with start-ups, research institutions, or other industry players. Through these partnerships, corporations can gain access to novel technologies, broaden their market reach, and expedite the pace of innovation. Additionally, diversification emerges as another adaptation strategy, enabling companies to venture into adjacent markets or therapeutic areas. This not only helps in mitigating risks but also enables them to capitalise on emerging opportunities within the healthcare landscape. Furthermore, many traditional corporations opt for M&A to bolster their market position, acquire specialised capabilities, or tap into new customer segments. Collectively, these strategies empower traditional corporations to navigate industry transitions towards customised care, foster sustained growth, and uphold their competitive edge.
 
Takeaways
`
This Commentary highlights the need for companies to re-evaluate their strategies in response to the industry's shift toward personalised care, a force shaping the future of healthcare delivery. It suggests traditional enterprises should proactively address challenges such as regulatory compliance, data security, and technological adoption barriers. Yet, within these challenges lie significant opportunities for growth and innovation. By pursuing strategic partnerships, investing in R&D, diversifying, and engaging in M&A, corporations can lead in the era of customised care, influencing healthcare's trajectory. Despite obstacles, the outlook for traditional enterprises is promising, driven by technological advancements and global healthcare demands. Success, however, depends on their agility, resilience, and proactive adaptation to the evolving landscape. By leveraging innovation and fostering collaboration, traditional MedTechs can navigate complexity and continue to drive positive transformation within the industry.
view in full page